Rare Disease market access in the MENA and Nordic regions

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/01/eb/01/01eb0117-bd8a-3808-0fc1-54e85d028d9e/mza_5094890008854355116.jpg/600x600bb.jpg

Pharma Market Access Insights - from Petauri Evidence

Petauri Evidence

70 episodes

3 weeks ago

Send us a text In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to: - Sarah Everest Ford (Programme Director, Health and Care Partnership) - Patrick McGee (Deputy Programme Director for Pathology, Lancashire & South Cumbria) - Prof. Phil Richardson (Former Dorset ICS System Commissioning Director; now Chief Innovation Officer, Petauri Evidence) Together, they explore the implications of changing N...

All content for Pharma Market Access Insights - from Petauri Evidence is the property of Petauri Evidence and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Rare Disease market access in the MENA and Nordic regions

Pharma Market Access Insights - from Petauri Evidence

59 minutes

1 year ago

Rare Disease market access in the MENA and Nordic regions

Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?In this webinar, our Global Market Access tea...